Ticagrelor: A Novel Drug for an Old Problem

Author(s): Andrea Rognoni, Chiara Cavallino, Alessandro Lupi, Gioel G. Secco, Alessia Veia, Sara Bacchini, Roberta Rosso, Sandra Brunelleschi, Francesco Rametta, Angelo S. Bongo

Journal Name: Recent Patents on Cardiovascular Drug Discovery
Continued as Recent Advances in Cardiovascular Drug Discovery

Volume 9 , Issue 1 , 2014


Cardiovascular disease and in particular, acute coronary syndromes are one of the principle causes of death in the industrialized countries. In the setting of acute coronary syndromes (both ST – segment or non ST - segment elevation myocardial infarction), platelets aggregation plays a key and central role in their development. Platelets are the mediators of hemostasis at sites of vascular injury, but they also mediate pathologic thrombosis; activated platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion promoting atherothrombotic disease. Recent patent relates to the methods and devices for treating atherosclerosis and to prevent in-stent restenosis or thrombosis. Because of the importance of platelets involvement in the initiation and propagation of thrombosis, antiplatelet drugs have a source of research; in the recent past, new antiplatelet drugs (such as ticagrelor) have been studied and placed in the routine therapy. The aim of this paper is to summarize the pharmacological properties and the clinical characteristics of ticagrelor.

Keywords: Acute coronary syndromes, atherosclerosis, antiplatelet therapy, bleeding, thrombosys.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 16 January, 2015
Page: [51 - 57]
Pages: 7
DOI: 10.2174/1574890109666140901150224

Article Metrics

PDF: 38